VEGFR3 / FLT-4 Antibody (Antigen Affinity Purified)

VEGFR3 / FLT-4 Antibody ( Antigen Affinity Purified ) Datasheet

VEGFR3 / FLT-4 Antibody Product Information

• Immunogen: Recombinant Mouse VEGFR3 / FLT-4 protein (Catalog#50584-M08H)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Mouse VEGFR3 / FLT-4 (rM VEGFR3 / FLT-4; Catalog#50584-M08H; P35917-1; Met 1-Glu 775). VEGFR3 / FLT-4 specific IgG was purified by Mouse VEGFR3 / FLT-4 affinity chromatography.

VEGFR3 / FLT-4 Antibody Usage Guide

• Specificity: Recombinant Mouse VEGFR3 / FLT-4 protein (Catalog#50584-M08H)
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse FLT4 in WB. Using a DAB detection system, the detection limit for Mouse FLT4 is approximately 2 ng/lane under non-reducing conditions and 4 ng/lane under reducing conditions.
• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse FLT4. The detection limit for Mouse FLT4 is approximately 0.00975 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

VEGFR3 / FLT-4 Antibody Background

VEGF R3 (Flt-4), together with the other two members VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). They share the similar structure characteristics of seven immunoglobulin-like repeats in their extracellular domain, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. The fifth Ig domain of VEGFR3 ECD is proteolytically cleaved and the resulting polypeptides remain linked by two disulfide-bonds. VEGFR3/FLT-4 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. Upon ligand binding, VEGFR3/FLT-4 become activated through transphosphorylation after homodimerization and subsequently interacts with the adaptor proteins such as SHC and GRB2, and thus mediates the cellular responses of VEGF. Both VEGF-C and VEGF-D have been identified as ligands for VEGF R3. The VEGF receptors are essential for vasculogenesis and angiogenesis, while VEGFR3/FLT-4 plays a significant role in ligand-mediated lymphangiogenesis. Mutation in this gene is associated with the primary lymphedema which is a rare genetic condition with both autosomal dominant and autosomal recessive modes of inheritance.

References

1. Pajusola, K. et al., 1992, Cancer. Res. 52: 5738-5743.
2. Pajusola, K. et al., 1994, Oncogene. 9: 3545-3555.
3. Achen, M.G. et al., 1998, Proc. Natl. Acad. Sci. 95: 548-553.
4. Tammela, T. et al., 2008, Nature. 454: 656-660.
5. Finegold, D.N. et al., 2008, Lymphat. Res. Biol. 6: 65-68.
6. Iljin, K. et al., 2001, FASEB. J. 15: 1028-1036.